Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$9.98
-0.26 (-2.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-49.5M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.2B
P/E
124.8x
↑EV/EBITDA
46.1x
↑ROE
1.5%
↑Gross Margin
22.1%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-4.2%
FCF CAGR
—
FCF margin
-9.9%
FCF / Net income
-1.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $453.3M · net income $34.9M · FCF $-44.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $453.3M | $453.3M | $445.9M | $663.0M | $514.9M |
| Net Income | $34.9M | $34.9M | $91.5M | $176.1M | $125.8M |
| EBITDA | $84.8M | $84.8M | $126.2M | $224.8M | $169.5M |
| EPS | 0.08 | 0.08 | 0.22 | 0.42 | 0.30 |
| Gross Margin | 22.1% | 22.1% | 28.8% | 40.2% | 28.9% |
| Operating Margin | 1.6% | 1.6% | 7.2% | 22.6% | 15.9% |
| Net Margin | 7.7% | 7.7% | 20.5% | 26.6% | 24.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 17.18 | 17.18 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-44.8M | $-44.8M | $-68.4M | $-49.5M | $174.8M |
| Returns | |||||
| ROE | 1.5% | 1.5% | 4.0% | 7.5% | 5.5% |
| Valuation | |||||
| P/E | 124.75 | 124.75 | 70.34 | 34.98 | 60.13 |
| EV/EBITDA | 46.11 | 46.11 | 46.78 | 19.90 | 33.70 |
| P/B | 1.92 | 1.92 | 2.79 | 2.61 | 3.32 |
| Growth & Yield | |||||
| Revenue Growth | 1.7% | 1.7% | -32.8% | 28.8% | — |
| EPS Growth | -63.6% | -63.6% | -47.7% | 38.6% | — |
| Dividend Yield | 1.7% | 1.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
122.9%
EPS terminal req.
$0.89
Spread vs growth
-186.5%
5Y implied EPS CAGR
68.0%
EPS terminal req.
$1.07
Spread vs growth
-131.7%
10Y implied EPS CAGR
36.0%
EPS terminal req.
$1.73
Spread vs growth
-99.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.1%
Start / end P/E
55.9x → 124.7x
EPS bridge
0.22 → 0.08
Residual
-78.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.